Disclosures for "Miv-cel CD19 CAR T-Cell Therapy Shows Efficacy and Safety in Stiff Person Syndrome in a Pivotal, Multicenter, Phase 2 Study (KYSA-8)"
-
Author has nothing to disclose
-
The institution of Dr. Zekeridou has received research support from Roche/Genentech. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care. Dr. Zekeridou has received intellectual property interests from a discovery or technology relating to health care.
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Dr. Lowe has received research support from Kyverna Therapeutics.
-
Sadie Eggmann has nothing to disclose.
-
The institution of Dr. McKeon has received research support from National Institutes of Health. Dr. McKeon has received intellectual property interests from a discovery or technology relating to health care. Dr. McKeon has received intellectual property interests from a discovery or technology relating to health care. Dr. McKeon has received publishing royalties from a publication relating to health care.
-
Author has nothing to disclose
-
Dr. Rakocevic has nothing to disclose.
-
Author has nothing to disclose
-
Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Newsome has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Newsome has received research support from Biogen. The institution of Dr. Newsome has received research support from Genentech/Roche. The institution of Dr. Newsome has received research support from Department of Defense. The institution of Dr. Newsome has received research support from Patient Centered Outcomes Research Institute. The institution of Dr. Newsome has received research support from National MS Society. The institution of Dr. Newsome has received research support from Lundbeck. The institution of Dr. Newsome has received research support from Sanofi. The institution of Dr. Newsome has received research support from Kyverna Therapeutics. Dr. Newsome has received personal compensation in the range of $10,000-$49,999 for serving as a Lead PI for Clinical Trial with Roche.
-
Dr. Chou has received personal compensation for serving as an employee of Kyverna Therapeutics. Dr. Chou has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Van Blarcom has received personal compensation for serving as an employee of Kyverna Therapeutics. Dr. Van Blarcom has stock in Kyverna Therapeutics. Dr. Van Blarcom has stock in Allogene Theraepeutics.
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Dr. Tooker has received personal compensation for serving as an employee of Prothena Biosciences, Inc. Dr. Tooker has received personal compensation for serving as an employee of Kyverna Therapeutics, Inc. Dr. Tooker has or had stock in Prothena Biosciences, Inc.Dr. Tooker has or had stock in Kyverna Therapeutics, Inc.
-
Dr. Mehta has received personal compensation for serving as an employee of Kyverna Therapeutics. Dr. Mehta has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atara Biotherapeutics. Dr. Mehta has or had stock in Kyverna Therapeutics.Dr. Mehta has or had stock in Atara Biotherapeutics.
-
Dr. Grayson has received personal compensation for serving as an employee of Kyverna Therapeutics.
-
Dr. Gehchan has received personal compensation for serving as an employee of Kyverna Tx. Dr. Gehchan has received personal compensation for serving as an employee of Eli Lilly. Dr. Gehchan has stock in Eli Lilly.
-
Author has nothing to disclose